Medline Posts 14.8% Q4 Sales Increase to $7.8B, Guides 8–9% Growth
Medline’s Q4 net sales rose 14.8% to $7.8B driven by higher volumes in Medline Brand and Supply Chain Solutions, while net income fell 37.7% to $180M due to IPO and tariff costs. The company projects 8–9% organic sales growth and $3.5–3.6B adjusted EBITDA for 2026.
1. Q4 Sales and Income Results
In Q4 2025, Medline reported net sales of $7.8 billion, a 14.8% increase driven by higher volumes in its Medline Brand and Supply Chain Solutions segments. Net income declined 37.7% to $180 million as IPO-related expenses, higher operating costs and tariff costs weighed on profitability, while adjusted EBITDA held steady at $805 million.
2. Full-Year 2025 Performance
For the full year, net sales rose 11.5% to $28.4 billion, bolstered by $2.4 billion in new customer signings. Net income dipped 3.6% to $1.2 billion due to investments in headcount and tariffs, yet adjusted EBITDA climbed 3.2% to $3.5 billion.
3. 2026 Outlook and Guidance
Medline projects organic sales growth between 8% and 9% for 2026 and expects adjusted EBITDA to reach $3.5 billion to $3.6 billion. The company highlights its expanded distribution network and broad product portfolio as key drivers for sustainable long-term growth following its transition to a public company.